Ibyerekeye-kanseri / kuvura / ivuriro-ibigeragezo / indwara / yoroshye-tissue-sarcoma / kuvura

Kuvura Igeragezwa rya Clinical for Tissue Tissue Sarcoma

Igeragezwa rya Clinical ni ubushakashatsi bwubushakashatsi burimo abantu. Igeragezwa rya clinique kururu rutonde ni ryoroshye kuvura sarcoma. Ibigeragezo byose kurutonde bishyigikiwe na NCI.

Amakuru yibanze ya NCI kubyerekeye ibizamini byamavuriro asobanura ubwoko nicyiciro cyibigeragezo nuburyo bikorwa. Igeragezwa rya Clinical rireba uburyo bushya bwo kwirinda, gutahura, cyangwa kuvura indwara. Urashobora gushaka gutekereza kubijyanye no kwitabira ikizamini cyamavuriro. Vugana na muganga wawe kugirango agufashe guhitamo niba umwe akubereye.

Erdafitinib mu kuvura abarwayi bafite ibibyimba byongeye gusubiranamo cyangwa kuvunika, Lymphoma itari Hodgkin, cyangwa Indwara ya Histiocytic hamwe na Mutation ya FGFR (Ikigeragezo cyo kuvura abana bato)

Iki cyiciro cya II MATCH yikigereranyo cyabana cyerekana uburyo erdafitinib ikora neza mukuvura abarwayi bafite ibibyimba bikomeye, lymphoma itari Hodgkin, cyangwa indwara ya histiocytic yakwirakwiriye ahandi mu mubiri kandi bakagaruka cyangwa ntibitabira kuvura hamwe na mutation ya FGFR. Erdafitinib irashobora guhagarika imikurire ya selile ya kanseri ihagarika zimwe mu misemburo ikenewe kugirango imikurire ikure.

Aho uherereye: ahantu 107

Tazemetostat mu kuvura abarwayi bafite ibibyimba bisubirwamo cyangwa bivanze cyane, Lymphoma itari Hodgkin, cyangwa Indwara ya Histiocytic hamwe na EZH2, SMARCB1, cyangwa SMARCA4 ihinduka ry’imiterere (Ikigeragezo cyo kuvura abana bato)

Iki cyiciro cya II Ikigereranyo cy’abana bato cyiga uburyo tazemetostat ikora neza mukuvura abarwayi bafite ibibyimba bikomeye, lymphoma itari hodgkin, cyangwa indwara ya histiocytic yakwirakwiriye ahandi mu mubiri kandi bakagaruka cyangwa ntibitabira kwivuza kandi bafite EZH2, SMARCB1 , cyangwa SMARCA4 ihindagurika rya gene. Tazemetostat irashobora guhagarika imikurire ya selile yibibyimba ihagarika zimwe mu misemburo ikenewe kugirango imikurire ikure.

Aho uherereye: 109

PI3K / mTOR Inhibitor LY3023414 mukuvura abarwayi bafite ibibyimba byongeye kugaruka cyangwa kuvunika, Lymphoma itari Hodgkin, cyangwa Indwara ya Histiocytic hamwe na TSC cyangwa PI3K / MTOR (Ikigeragezo cyo kuvura abana bato)

Iki cyiciro cya II Ikigereranyo cyabana bato cyiga uburyo PI3K / mTOR inhibitor LY3023414 ikora neza mukuvura abarwayi bafite ibibyimba bikomeye, lymphoma itari Hodgkin, cyangwa indwara ya histiocytic hamwe na TSC cyangwa PI3K / MTOR ihinduka ryakwirakwiriye ahandi mu mubiri (metastatike) na bagarutse (gusubiramo) cyangwa ntibitabira kwivuza (retractory). PI3K / mTOR inhibitor LY3023414 irashobora guhagarika imikurire ya selile ya kanseri ihagarika zimwe mu misemburo ikenewe kugirango imikurire ikure.

Aho uherereye: ahantu 107

Palbociclib mu kuvura abarwayi bafite ibibyimba byongeye kugaruka cyangwa kuvunika Rb Ibyiza Bikomeye Byibibyimba Byinshi, Lymphoma itari Hodgkin, cyangwa Indwara ya Histiocytic hamwe no Guhindura Guhindura Ingirabuzimafatizo (Ikizamini cyo kuvura abana bato)

Iki cyiciro cya II Ikigereranyo cy’abana bato cyiga uburyo palbociclib ikora neza mukuvura abarwayi bafite ibibyimba byiza bya Rb, lymphoma itari Hodgkin, cyangwa indwara ya histiocytic hamwe noguhindura (mutation) mumyanya mikorere ya selile yakwirakwiriye ahandi mumubiri kandi yaje inyuma cyangwa ntusubize kwivuza. Palbociclib irashobora guhagarika imikurire ya selile ya kanseri ihagarika zimwe mu misemburo ikenewe kugirango imikurire ikure.

Aho uherereye: ahantu 97

Larotrectinib mu kuvura abarwayi bafite ibibyimba byongeye gusubirana cyangwa byangiritse, Lymphoma itari Hodgkin, cyangwa Indwara ya Histiocytic hamwe na NTRK Fusion (Ikigeragezo cyo kuvura abana bato)

Iki cyiciro cya II UMUKINO W'ABANYARWANDA wiga uburyo larotrectinib ikora neza mukuvura abarwayi bafite ibibyimba bikomeye, lymphoma itari Hodgkin, cyangwa indwara ya histiocytic hamwe na fusion ya NTRK yakwirakwiriye ahandi mumubiri kandi yagarutse cyangwa ntiyitabira kwivuza. Larotrectinib irashobora guhagarika imikurire ya selile kanseri ihagarika imisemburo ikenewe kugirango imikurire ikure.

Aho uherereye: 109

Cabozantinib-S-Malate mu kuvura abarwayi bakiri bato hamwe na Sarcomas isubirwamo, Yisubiraho, cyangwa Yasuzumwe vuba, Wilms Tumor, cyangwa Ibibyimba Bidasanzwe.

Iki cyiciro cya II cyikigereranyo cyiga uburyo cabozantinib-s-malate ikora neza mukuvura abarwayi bato barwaye sarcomas, ikibyimba cya Wilms, cyangwa ibindi bibyimba bidasanzwe byagarutse, ntibitabira ubuvuzi, cyangwa basuzumwe vuba. Cabozantinib-s-malate irashobora guhagarika imikurire ya selile yibibyimba ihagarika zimwe mu misemburo ikenewe mu mikurire yikibyimba no gukura kwamaraso.

Aho uherereye: ahantu 137

Olaparib mu kuvura abarwayi bafite ibibyimba byongeye gusubirana cyangwa byangiritse, Lymphoma itari Hodgkin, cyangwa Indwara ya Histiocytic ifite inenge ziri muri ADN zangiza ibyangiritse (Ikigeragezo cyo kuvura abana bato)

Iki cyiciro cya II Ikigereranyo cy’abana bato cyiga uburyo olaparib ikora neza mukuvura abarwayi bafite ibibyimba bikomeye, lymphoma itari Hodgkin, cyangwa indwara ya histiocytic ifite inenge muri acide deoxyribonucleic (ADN) yangiza ingirabuzima fatizo zo gusana zakwirakwiriye ahandi mu mubiri (zateye imbere) na bagarutse (basubiwemo) cyangwa ntibitabira kwivuza (retractory). Olaparib irashobora guhagarika imikurire ya selile yibibyimba ihagarika imisemburo ikenewe kugirango imikurire ikure.

Aho uherereye: ahantu 105

Vemurafenib mu kuvura abarwayi bafite ibibyimba byongeye gusubirana cyangwa byangiritse, Lymphoma itari Hodgkin, cyangwa Indwara ya Histiocytic hamwe na BRAF V600 ihinduka (Ikigeragezo cyo kuvura abana bato)

Iki cyiciro cya II UMUKINO W'abana bato wiga uburyo vemurafenib ikora neza mukuvura abarwayi bafite ibibyimba bikomeye, lymphoma itari Hodgkin, cyangwa indwara ya histiocytic hamwe na mutation ya BRAF V600 yakwirakwiriye ahandi mu mubiri kandi yagarutse cyangwa ntiyitabira kwivuza. Vemurafenib irashobora guhagarika imikurire ya selile yibibyimba ihagarika imisemburo ikenewe kugirango imikurire ikure.

Aho uherereye: ahantu 106

Atezolizumab mu kuvura abarwayi bafite Alveolar Yasuzumwe na Metastatike Yoroheje Igice cya Sarcoma idashobora gukurwaho no kubagwa

Iki cyiciro cya kabiri cyikigereranyo cyiga uburyo atezolizumab ikora neza mukuvura abarwayi bafite alveolar yoroshye igice cya sarcoma itavuwe, yakwirakwiriye aho yatangiriye ahandi hantu mumubiri kandi ntishobora gukurwaho no kubagwa. Immunotherapy hamwe na antibodiyite za monoclonal, nka atezolizumab, irashobora gufasha umubiri wumubiri gutera kanseri, kandi irashobora kubangamira ubushobozi bwingirabuzimafatizo yibibyimba gukura no gukwirakwira.

Aho uherereye: ahantu 39

Nivolumab na Ipilimumab mu kuvura abarwayi banduye virusi itera sida Yongeye kwisubiraho cyangwa yangiritse ya Classic Hodgkin Lymphoma cyangwa Ibibyimba bikomeye Bipima cyangwa bidashobora gukurwaho no kubagwa

Iki cyiciro cya I cyigeragezo cyiga ku ngaruka n’igipimo cyiza cya nivolumab iyo gitanzwe na ipilimumab mu kuvura abarwayi bafite virusi itera immunodeficiency (virusi itera SIDA) ifitanye isano na lymphoma ya kera ya Hodgkin yagarutse nyuma yigihe runaka cyo gutera imbere cyangwa kutitabira kwivuza, cyangwa ibibyimba bikomeye ibyo yakwirakwiriye ahandi mu mubiri cyangwa ntishobora gukurwaho no kubagwa. Immunotherapy hamwe na antibodiyite za monoclonal, nka ipilimumab na nivolumab, birashobora gufasha umubiri wumubiri kwibasira kanseri, kandi bishobora kubangamira ubushobozi bwingirabuzimafatizo yibibyimba gukura no gukwirakwira. Ipilimumab ni antibody ikora kurwanya molekile yitwa cytotoxic T-lymphocyte antigen 4 (CTLA-4). CTLA-4 igenzura igice cya sisitemu yumubiri wawe uyifunga. Nivolumab ni ubwoko bwa antibody yihariye ku rupfu rwabantu rwateguwe 1 (PD-1), poroteyine ishinzwe gusenya ingirabuzimafatizo. Guha ipilimumab hamwe na nivolumab birashobora gukora neza mukuvura abarwayi ba virusi itera sida ya Hodgkin ya lymphoma cyangwa ibibyimba bikomeye ugereranije na ipilimumab na nivolumab yonyine.

Aho uherereye: ahantu 28

MDM2 Inhibitor AMG-232 hamwe nubuvuzi bwimirasire mukuvura abarwayi hamwe na Sarcoma yumubiri woroshye

Iki cyiciro cyibigeragezo cyiga ingaruka za MDM2 inhibitor AMG-232 hamwe nubuvuzi bwimirasire mukuvura abarwayi bafite sarcoma yoroheje. MDM2 inhibitor AMG-232 irashobora guhagarika imikurire ya selile ya kanseri ihagarika zimwe mu misemburo ikenewe kugirango imikurire ikure. Guha MDM2 inhibitor AMG-232 hamwe nubuvuzi bwimirasire mbere yo kubagwa bishobora gutuma ikibyimba gito kandi kigabanya ubwinshi bwimyenda isanzwe igomba kuvaho.

Aho uherereye: ahantu 27

Nivolumab hamwe na Ipilimumab cyangwa idafite mu kuvura abarwayi bato bafite ibibyimba bisubirwamo cyangwa bikabije cyangwa Sarcomas

Iki cyiciro cya I / II cyiga ingaruka mbi nigipimo cyiza cya nivolumab mugihe gitanzwe hamwe na ipilimumab cyangwa kitarimo kugira ngo barebe uburyo bakora neza mukuvura abarwayi bato bafite ibibyimba bikomeye cyangwa sarcomasi byagarutse (byongeye) cyangwa ntibitabira kwivuza (byongeye) kwanga). Immunotherapy hamwe na antibodiyite za monoclonal, nka nivolumab na ipilimumab, irashobora gufasha sisitemu yumubiri yumubiri gutera kanseri, kandi irashobora kubangamira ubushobozi bwingirabuzimafatizo yibibyimba gukura no gukwirakwira. Kugeza ubu ntiharamenyekana niba nivolumab ikora neza wenyine cyangwa hamwe na ipilimumab mu kuvura abarwayi bafite ibibyimba bikomeye cyangwa byanga bikunze cyangwa sarcomas.

Aho uherereye: ahantu 24

Selinexor muri Liposarcoma Yambere

Ubu ni uburyo butemewe, butandukanye, buhumye-buhumyi, bugenzurwa na platbo, icyiciro cya 2-3 cy’abarwayi basuzumwe na liposarcoma yateye imbere idashobora gukemurwa. Abarwayi bagera kuri 279 bose bazatoranwa kwiga kuvura (selinexor cyangwa placebo).

Aho uherereye: ahantu 21

(VOYAGER) Kwiga Avapritinib vs Regorafenib mu barwayi hamwe na GISTI Yateye imbere idashobora gukemurwa cyangwa Metastatike

Ubu ni label ifunguye, itabishaka, icyiciro cya 3 kubarwayi bafite GIST yateye imbere idashobora gukemurwa cyangwa metastatike (GIST yateye imbere) ya avapritinib (izwi kandi nka BLU-285) na regorafenib kubarwayi bavuwe na imatinib hamwe na TKI 1 cyangwa 2.

Aho uherereye: ahantu 14

Icyiciro cya 1 Kwiga EZH2 Inhibitor Tazemetostat mubintu byabana hamwe nibisubirwamo cyangwa bivunika INI1-Ibibyimba bibi cyangwa Sarcoma ya Synovial

Nicyiciro cya I, fungura-label, dose escalation hamwe nubushakashatsi bwagutse hamwe na BID umunwa wa tazemetostat. Ibintu bizerekanwa kugirango byemererwe mugihe cyiminsi 14 uhereye igihe cyateganijwe cya mbere cya tazemetostat. Inzira yo kuvura izaba iminsi 28. Isuzuma ryibisubizo rizasuzumwa nyuma yibyumweru 8 bivurwa hanyuma buri byumweru 8 mugihe uri kwiga. Ubushakashatsi bufite ibice bibiri: Dose Escalation no Kwagura Dose. Kwiyongera kwa Dose kubintu bifite malignancies zikurikira zisubirwamo / zisubiza inyuma: - Ibibyimba bya Rhabdoid: - Ikibyimba kidasanzwe cya teratoide rhabdoid (ATRT) - Ikibyimba cya Rhabdoid (MRT) - Ikibyimba cya Rhabdoid cy'impyiko (RTK) - Ibibyimba byatoranijwe bifite ibimenyetso bya Rhabdoid - INI1-mbi :

Aho uherereye: ahantu 14

Adavosertib na Hydrochloride ya Irinotecan mu kuvura abarwayi bakiri bato bafite ibibyimba byongeye cyangwa byangiritse.

Iki cyiciro cya I / II cyiga ku ngaruka n'ingaruka nziza za adavosertib na hydrochloride ya irinotecan mu kuvura abarwayi bakiri bato bafite ibibyimba bikomeye byagarutse (byongeye) cyangwa bititabiriye ubuvuzi busanzwe (retractory). Adavosertib na hydrochloride ya irinotecan irashobora guhagarika imikurire ya selile yibibyimba ihagarika imisemburo ikenewe kugirango imikurire ikure.

Aho uherereye: ahantu 22

Icyiciro cya III Ikigeragezo cya Anlotinib muri Metastatic cyangwa Advanced Alveolar Yoroheje Igice cya Sarcoma, Leiomyosarcoma na Sarcoma ya Synovial

Ubu bushakashatsi busuzuma umutekano n’ingirakamaro bya hydrochloride ya AL3818 (anlotinib) mu kuvura metastatike cyangwa alveolar yoroshye igice cya sarcoma (ASPS), leiomyosarcoma (LMS), na sarcoma ya synovial (SS). Abitabiriye bose hamwe na ASPS bazahabwa gufungura-label AL3818. Abitabiriye hamwe na LMS cyangwa SS, AL3818 bazagereranwa na IV dacarbazine. Bibiri bya gatatu byabitabiriye bazahabwa AL3818, kimwe cya gatatu cyabitabiriye bazahabwa IV dacarbazine.

Aho uherereye: ahantu 14

Nab-Paclitaxel na Gemcitabine Hydrochloride mukuvura ingimbi cyangwa abakuze bato hamwe na Osteosarcoma isubirwamo cyangwa yangiritse, Ewing Sarcoma, Rhabdomyosarcoma, cyangwa Tissue Sarcoma

Iki cyiciro cya II cyigeragezwa cyiga uburyo nab-paclitaxel na hydrochloride ya gemcitabine ikora neza mukuvura ingimbi cyangwa abasore bakuze barwaye osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, cyangwa sarcoma yoroheje yoroheje yagarutse cyangwa ititabira kwivuza. Ibiyobyabwenge bikoreshwa muri chimiotherapie, nka nab-paclitaxel na hydrochloride ya gemcitabine, bikora muburyo butandukanye bwo guhagarika imikurire ya selile yibibyimba, haba mukwica selile, kubabuza gutandukana, cyangwa kubabuza gukwirakwira.

Aho uherereye: ahantu 18

Olaparib na Temozolomide mu kuvura abarwayi hamwe na Uterine Leiomyosarcoma yateye imbere, Metastatike, cyangwa idashobora gukemurwa

Iki cyiciro cya II cyikigereranyo cyiga olaparib na temozolomide mukuvura abarwayi barwaye nyababyeyi leiomyosarcoma (LMS) yakwirakwiriye ahandi mu mubiri (yateye imbere cyangwa metastatike) cyangwa idashobora gukurwaho no kubagwa (idasubirwaho). Olaparib irashobora guhagarika imikurire ya selile yibibyimba ihagarika imisemburo ikenewe kugirango imikurire ikure. Ibiyobyabwenge bikoreshwa muri chimiotherapie, nka temozolomide, bikora muburyo butandukanye bwo guhagarika imikurire ya selile yibibyimba, haba mukwica selile, kubabuza gutandukana, cyangwa kubabuza gukwirakwira. Gutanga olaparib na temozolomide birashobora gukora neza kuruta gutanga imiti yonyine mukuvura abarwayi bafite LMS.

Aho uherereye: ahantu 12

Umutekano, Ubworoherane na PK Kwiga DCC-2618 mubarwayi bafite Indwara mbi

Iki nicyiciro cya 1, fungura-label, ubushakashatsi bwambere-bwabantu (FIH) dose-escalation igamije gusuzuma umutekano, kwihanganira, pharmacokinetics (PK), pharmacodynamics (PD) nibikorwa byabanjirije antitumor ya DCC-2618, byatanzwe kumanwa. (PO), mu barwayi bakuze bafite indwara mbi. Ubushakashatsi bugizwe n'ibice 2, icyiciro cya dose-escalation nicyiciro cyo kwaguka.

Aho uherereye: ahantu 12

Nelfinavir Mesylate mukuvura abarwayi hamwe na Kaposi Sarcoma

Iki cyiciro cya kabiri cyikigereranyo cyiga uburyo nelfinavir mesylate ikora neza mukuvura abarwayi barwaye Kaposi sarcoma. Nelfinavir mesylate irashobora guhagarika imikurire ya selile yibibyimba ihagarika zimwe mumisemburo ikenewe kugirango imikurire ikure.

Aho uherereye: ahantu 11

sEphB4-HSA mu kuvura abarwayi hamwe na Kaposi Sarcoma

Iki cyiciro cya II cyigeragezwa cyiga recombinant EphB4-HSA fusion protein (sEphB4-HSA) mukuvura abarwayi barwaye Kaposi sarcoma. Recombinant EphB4-HSA poroteyine irashobora guhagarika imikurire yimitsi itanga amaraso kuri kanseri, kandi irashobora no kubuza selile kanseri gukura.

Aho uherereye: ahantu 10

Icyiciro cya II, Kwiga byinshi kuri EZH2 Inhibitor Tazemetostat mubintu bikuze hamwe na INI1-Ibibyimba bibi cyangwa byongeye / Sarcoma ya Sinovial

Iki nicyiciro cya II, multicenter, fungura-label, ukuboko kumwe, icyiciro cya 2 cya tazemetostat 800 mg BID yatanzwe kumunwa muminsi 28 yikurikiranya. Kugenzura amasomo kugirango hamenyekane abemerewe kwiga bizakorwa mugihe cyiminsi 21 uhereye igihe cya mbere cyateganijwe cya tazemetostat. Amasomo yujuje ibisabwa azandikwa muri imwe muri eshanu zishingiye ku bwoko bwibibyimba: - Cohort 1 (Ifunze kwiyandikisha): MRT, RTK, ATRT, cyangwa ibibyimba byatoranijwe bifite ibimenyetso bya rhabdoid, harimo kanseri ntoya ya kanseri yo mu bwoko bwa ovary hypercalcemic [SCCOHT], nayo bizwi nka malignant rhaboid tumor ya ovary [MRTO] - Cohort 2 (Ifunze kugirango yiyandikishe): Sarcoma isubirwamo cyangwa yananiranye hamwe na SS18-SSX yongeye gutondekanya - Cohort 3 (Ifunze kugirango yiyandikishe): Ibindi bibyimba bibi bya INI1 cyangwa ikibyimba gikomeye gifite EZH2 inyungu yimikorere (GOF) mutation, harimo:

Aho uherereye: ahantu 12

SARC024: Porotokole ya Blanket yo kwiga umunwa Regorafenib mu barwayi bafite Sarcoma Yatoranijwe.

Nubwo regorafenib yemerewe gukoreshwa mu barwayi bafite GIST igenda itera imbere nubwo imatinib na / cyangwa sunitinib hashingiwe ku makuru yo mu cyiciro cya II n'icyiciro cya III, ntabwo yasuzumwe mu buryo bwa gahunda ku barwayi bafite ubundi bwoko bwa sarcoma. Urebye ibikorwa bya sorafenib, sunitinib na pazopanib muri sarcoma yoroheje yoroheje, hamwe nibimenyetso byerekana ibikorwa bya sorafenib muri sarcoma ya osteogeneque ndetse birashoboka na sarcoma ya Ewing / Ewing, hashobora kubaho urugero rwo gusuzuma SMOKIs (molekile ntoya ya kinase inhibitor) nka regorafenib muri sarcomas. usibye GIST. Birazwi kandi ko SMOKIs (molekile ntoya yo mu kanwa inhibitor) nka regorafenib, sorafenib, pazopanib, na sunitinib zifite panne zuzuye za kinase zibujijwe icyarimwe. Nubwo bidahwanye,

Aho uherereye: ahantu 10

Umutekano, Ubworoherane na Pharmacokinetics ya Anti-PD-1 Antibody ya Monoclonal Antibody mubintu bifite Malignancies Yateye imbere

Intego y'ibanze ni ugusuzuma umutekano no kwihanganira Toripalimab mu masomo afite indwara mbi zateye imbere no gusuzuma icyiciro cya 2 gisabwa. Intego za kabiri ni: 1) gusobanura imiterere ya farumasi (PK) ya Toripalimab, 2) gusuzuma ibikorwa bya antipumor ya Toripalimab; 3) kumenya ubudahangarwa bwa Toripalimab; 4) gusuzuma ubuzima muri rusange. Intego zubushakashatsi ni: 1) gusuzuma biomarkers zishobora kuba zifitanye isano nibikorwa bya Toripalimab, 2) gusuzuma ingaruka za farumasi ya Toripalimab kuri reseptor yayo, iyangirika rya selile 1 (PD-1), hamwe ningaruka kuri sisitemu yumubiri. 3) gusuzuma akamaro ka PD-L1 & ibindi bimenyetso byubushakashatsi nkibinyabuzima bishobora gufasha muguhitamo amasomo akwiye yo kuvura TAB001,

Aho uherereye: ahantu 9